Abstract 4283
Background
SM-88 (D,L-alpha-metyrosine; racemetyrosine [USAN]) is a relatively non-toxic, targeted therapy based on the Warburg Effect. It may be well suited for pancreas cancer because of its ability to penetrate tumors and tolerability in compromised patients.
Methods
Subjects progressed on at least one line of chemotherapy were randomized to receive either 460 mg/d or 920 mg/d single agent SM-88 administered with low doses of methoxsalen, phenytoin, and sirolimus (MPS) in the dose selecting stage of this trial. The primary endpoint is response rate by BICR.
Results
As of April 2019, 49 subjects with stage IV pancreatic ductal adenocarcinoma with radiographically documented progressive disease were enrolled and randomized. Mean age was 66 (45 – 85); median of 2 prior lines (1 – 5+); baseline median CA19.9 was 2,674 (0.8 – 651,696). There were 22 disease related SAEs before drug treatment, including 6 Grade 5 events. SM-88 was well tolerated with only four treatment-related Grade 3/4 adverse events in two subjects (and no treatment-related Grade 5 events). 94% of treated subjects (46/49) experienced a total 365 AEs, with only 17% (63/365) at least possibly treatment related. CTCs at baseline were detected in 100% (mean 138 cells/4 ml) and fell in 79% (23/29) evaluable subjects from 153 to a nadir of 54 cells/4 ml (median reduction 63% [18% - 100%]). 12% (4/33) evaluable subjects showed CA19.9 declines (-8% to –97% decline within 3 months), three of which also showed CTC declines. Subjects have remained on treatment a median of 6.9 wks (1.7 – 23.1). While progressive upon entry, 21% (8 of 38 evaluable subjects) displayed stable disease or better at 2 months or beyond. Of the 38 evaluable subjects, 42% (16/38) were alive at 4 months post randomization, and 24% (9/38) were alive at 6 months, which parallels carry over effect previously observed with SM-88. EORTC QLQ-C30, -PAN26, and correlative assays were obtained including leptin, genomics, and NLR.
Conclusions
SM-88 demonstrated unconfirmed monotherapy effect with no meaningful toxicity in a preliminary assessment of this ongoing trial. With additional follow up, dose and patient populations will be selected for expansion.
Clinical trial identification
NCT03512756.
Editorial acknowledgement
Legal entity responsible for the study
Tyme Inc.
Funding
Tyme Inc.
Disclosure
A. Ocean: Advisory / Consultancy: Tyme Inc. M. Noel: Advisory / Consultancy: Tyme Inc. A. Wang-Gillam: Advisory / Consultancy: Tyme Inc. S. Pant: Advisory / Consultancy: Tyme Inc. G. Del Priore: Leadership role, Shareholder / Stockholder / Stock options, Full / Part-time employment, Officer / Board of Directors: Tyme Inc. V. Picozzi: Advisory / Consultancy: Tyme Inc. All other authors have declared no conflicts of interest.
Resources from the same session
1058 - Assessment of CPS+EG, Neo-Bioscore and modified Neo-Bioscore in breast cancer patients treated with preoperative systemic therapy: a multicenter cohort study
Presenter: LING XU
Session: Poster Display session 2
Resources:
Abstract
1156 - The concordance of treatment decision guided by Oncotype and the PREDICT tool in early stage breast cancer
Presenter: Hadar Goldvaser
Session: Poster Display session 2
Resources:
Abstract
3447 - Influence of first treatment delay on survival among breast cancer subtypes
Presenter: Irene Zarcos Pedrinaci
Session: Poster Display session 2
Resources:
Abstract
3505 - Clinical features of early-stage (I-III) triple-negative breast cancer (TNBC) patients with tumors exhibiting low-overall change in molecular profile after neoadjuvant therapy.
Presenter: Nour Abuhadra
Session: Poster Display session 2
Resources:
Abstract
5442 - Meta-analysis in HER2+ early breast cancer therapies and cost-effectiveness in a Brazilian perspective
Presenter: Marcos Magalhaes
Session: Poster Display session 2
Resources:
Abstract
1570 - Anti-mullerian hormone (AMH) levels and antral follicle counts (AFC) may predict ovarian reserves before systemic chemotherapy (SC) in women with breast cancer(BC); a prospective clinical study
Presenter: Cetin Ordu
Session: Poster Display session 2
Resources:
Abstract
2698 - Prognosis of selected triple negative apocrine breast cancer patients who did not receive adjuvant chemotherapy.
Presenter: Giuseppe Cancello
Session: Poster Display session 2
Resources:
Abstract
3104 - Novel Blood Based Circulating Tumor Cell Biomarker For Breast Cancer Detection
Presenter: Chun-Yu Liu
Session: Poster Display session 2
Resources:
Abstract
4631 - Multi-Gene Prognostic Signatures and Prediction of Pathological Complete Response of ER-Positive HER2-Negative Breast Cancer Patients to Neo-Adjuvant Chemotherapy
Presenter: Claudia Mazo
Session: Poster Display session 2
Resources:
Abstract
4632 - Impact of menopause status on breast cancer outcomes and amenorrhea incidence during adjuvant tailored dose dense chemotherapy
Presenter: Andri Papakonstantinou
Session: Poster Display session 2
Resources:
Abstract